Healthy controls in nonalcoholic fatty liver disease management

What is it about?

I, Dr. Saumya Pandey Ph.D., have endeavored to highlight the essence of healthy controls in non-alcoholic fatty liver disease with an overall biomedical research perspective. Scientific integrity, good clinical practice research including written informed consent of NAFLD cases and age-matched, disease-free healthy controls are warranted to enhance the quality quotient(s) of patient-centric research in liver diseases. Ethnicity, age, BMI are significant predictors of liver-related malignancies and/or carcinomas. Healthy controls with stringent inclusion criteria should be matched with histopathologically confirmed cases of NASH of specific genetic landscape so as to eventually design cost-effective predictive biomarkers in NAFLD management. Pharmacogenetics/genomics public health oriented studies would certainly lead to spectacular gains in our current understanding of NAFLD in ethnically disparate populations worldwide.

Featured Image

Why is it important?

I, Dr. Saumya Pandey PH.D., have comprehensive medical research experience in both States of New York, Texas and Nebraska, USA and Lucknow/Udaipur, India, and would like to advocate good clinical research in hepatology research with due written informed consent of study participants of differential sociocultural exposures and lifestyles. My successful research contribution highlights the significance of incorporating suitable controls stringently matched to NAFLD cases, so as to derive statistically significant interpretation of complex data-sets. Liver enzymes, biotransformation of metabolites, and homeostasis in the normal vs diseased liver should be studied with well-designed timeline-based research protocols; adequate sample size of cases and controls should be incorporated for drawing definitive conclusions.

Perspectives